European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus

Ory, Fernando de; Echevarría, José Manuel; Kafatos, George; Anastassopoulou, Cleo; Andrews, Nick; Backhouse, J. L.; Berbers, Guy A. M.; Bruckova, Blazena; Cohen, Dani; Melker, Hester E. de; Davidkin, Irja; Gabutti, Giovanni; Hesketh, Louise; Johansen, Kari; Jokinen, Sari; Jones, L.; Linde, A; Miller, E. C.; Mossong, Joël; Nardone, Anthony; Rota, Maria Cristina; Sauerbrei, Andreas; Schneider, François; Smetana, Zehava; Tischer, Annedore; Tsakris, Athanassios; Vranckx, R.

doi:10.1016/j.jcv.2006.01.017

Cited by 41 publications

(40 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concentration of VZV-specific IgG antibody (VZV-IgG) in serum was measured using a commercial enzyme-linked immunosorbent assay (Dade-Behring Enzygnost Immunoassay kit) as already described. Corrected absorbance values were converted to log 10 mIU/ml and the results were classified as negative (values Ͻ50 mIU/ml), equivocal (between 50 and 100 mIU/ml), and positive (Ͼ100 mIU/ml) according to the manufacturer's recommendations (13).…”

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids

Pileggi¹,

Souza²,

Ferriani³

2010

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To evaluate the safety and immunogenicity of varicella vaccine (VV) in susceptible patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Methods. Twenty-five patients with juvenile rheumatic diseases (ages 2-19 years) and 18 healthy children and adolescents (ages 3-18 years) received a single dose of VV. All 25 patients were receiving methotrexate; 13 were also receiving prednisone and 5 were also receiving other disease-modifying antirheumatic drugs. None of the vaccinated patients or controls had a previous history of varicella. Anti-varicella-zoster virus IgG antibody (anti-VZV-IgG) titers were measured by enzyme-linked immunosorbent assay immediately before, 4 -6 weeks after, and 1 year after vaccination. The patients were monitored prospectively for adverse reactions related to the vaccine, exposure, and occurrence of varicella. Disease activity was assessed 3 months before and 3 months after VV. Conclusion. VV appears to be safe in patients with juvenile rheumatic diseases receiving methotrexate, as long as continuous prospective vigilance for side effects is performed. Results. Twenty patients and all of the controls had negative preimmunization titers of VZV-IgG

show abstract

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids

Pileggi¹,

Souza²,

Ferriani³

2010

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…This methodology has been applied successfully for various vaccine-preventable infections during the ESEN projects, i.e. : (i) measles, mumps, rubella [16,20] ; (ii) pertussis [17] ; (iii) diphtheria [19]) ; (iv) VZV [18] ; and (v) HBV [21]. The present collaborative work describes the development of a standardization procedure that allows for direct comparisons of HAV seroprevalence data generated at 15 European laboratories.…”

Section: Discussionmentioning

confidence: 99%

“…However, inter-laboratory variation, even when using the same EIA and international standards, is a well-recognized problem [15][16][17][18][19][20][21]; accordingly, differences mostly in sensitivity, but also in specificity, have been reported for both commercial and in-house anti-HAV assays [22][23][24][25][26][27][28][29][30][31]. Standardization is a methodological approach that provides a means to overcome this limitation and to ensure the direct comparability of seroepidemiological results obtained during the project [32].…”

Section: Introductionmentioning

confidence: 99%

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries

Anastassopoulou

Kafatos²,

Nardone³

et al. 2008

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYThe European Sero-Epidemiology Network 2 (ESEN2) aimed to compare serological results of vaccine-preventable diseases across Europe. To ensure direct inter-country comparability of hepatitis A virus antibody (anti-HAV) measurements, a standardization panel of 150 sera was developed by a designated reference laboratory and tested by participating national laboratories using assays of choice ; each country's results were subsequently regressed against those of the reference laboratory. Quantitatively, the assays were generally highly correlated (R 2 >0 . 90). Nevertheless, qualitative comparisons indicated that results obtained with different assays may differ despite the usage of well-established international and local standards. To a great extent standardization successfully alleviated such differences. The generated standardization equations will be used to convert national serological results into common units to enable direct international comparisons of HAV seroprevalence data. The results of this study are expected to contribute to the evaluation and potential improvement of the currently employed immunization strategies for hepatitis in Europe.

show abstract

“…They are generally sufficiently sensitive in subjects with a history of natural infection, but not sufficiently sensitive to detect seroconversion after vaccination as the antibody titres induced by vaccination are a logarithm lower than in the case of natural infection [5,30,54,380,393,397] . In vaccinated subjects, the tests are less sensitive than FAMA as studies have found that 58%-88% of the subjects who were negative or borderline at ELISA were positive to FAMA, which uses surface antigens [91,96,402,403] .…”

Section: Elisas and Eiasmentioning

confidence: 99%

“…Microbiology laboratory in mother-child VZV infection standardised tests has led to the production of CLIAs against international standards. The proposed cut-off values are 150 mIU/mL [414] or 100 mIU/mL (negative < 50 mIU/mL; doubtful 50-100 mIU/mL; positive > 100 mIU/mL) [327,403] . Their ability to give a quantitative result makes it easier to distinguish protected and unprotected subjects: For example, when they were used before VZIG administration to test women exposed to VZV during pregnancy, it was found that the women with CLIA (or TRFIA) values of < 100 mIU/mL were more likely to develop varicella than those with values of > 100 mIU/mL [253] .…”

Section: Gpelisamentioning

confidence: 99%

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Paschale

Clerici

2016

WJV

View full text Add to dashboard Cite

Varicella-zoster virus, which is responsible for varicella (chickenpox) and herpes zoster (shingles), is ubiquitous and causes an acute infection among children, especially those aged less than six years. As 90% of adults have had varicella in childhood, it is unusual to encounter an infected pregnant woman but, if the disease does appear, it can lead to complications for both the mother and fetus or newborn. The major maternal complications include pneumonia, which can lead to death if not treated. If the virus passes to the fetus, congenital varicella syndrome, neonatal varicella (particularly serious if maternal rash appears in the days immediately before or after childbirth) or herpes zoster in the early years of life may occur depending on the time of infection. A Microbiology laboratory can help in the diagnosis and management of mother-child infection at four main times: (1) when a pregnant woman has been exposed to varicella or herpes zoster, a prompt search for specific antibodies can determine whether she is susceptible to, or protected against infection; (2) when a pregnant woman develops clinical symptoms consistent with varicella, the diagnosis is usually clinical, but a laboratory can be crucial if the symptoms are doubtful or otherwise unclear (atypical patterns in immunocompromised subjects, patients with post-vaccination varicella, or subjects who have received immunoglobulins), or if there is a need for a differential diagnosis between varicella and other types of dermatoses with vesicle formation; (3) when a prenatal diagnosis of uterine infection is required in order to detect cases of congenital varicella syndrome after the onset of varicella in the mother; and (4) when the baby is born and it is necessary to confirm a diagnosis of varicella (and its complications), make a differential diagnosis between varicella and other diseases with similar symptoms, or confirm a causal relationship between maternal varicella and malformations in a newborn. Core tip: Although varicella during pregnancy is infrequent and congenital varicella syndrome (CVS) is rare, every available means should be used to prevent and diagnose them. Microbiology laboratories can be crucial in these situations: Evaluating a mother's immune status with sensitive and specific tests for the detection of antibodies; allowing a rapid diagnosis with molecular biology tests when a clinical manifestation may be due to different etiologies; following pregnant women with varicella for the prenatal diagnosis of CVS with close collaboration between molecular biology investigators and specialists in imaging diagnostics.De Paschale M, Clerici P. Microbiology laboratory and the management of mother-child varicella-zoster virus infection. World

show abstract

European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus

Cited by 41 publications

References 18 publications

Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids

Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids

The European Sero-Epidemiology Network 2 (ESEN2): standardization of assay results for hepatitis A virus (HAV) to enable comparisons of seroprevalence data across 15 countries

Microbiology laboratory and the management of mother-child varicella-zoster virus infection

Contact Info

Product

Resources

About